Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr;14(Suppl 1):4-8.
doi: 10.6004/jadpro.2023.14.3.15. Epub 2023 Apr 1.

Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes

Donald C Moore  1 , Andrew S Guinigundo  2
Affiliations
Review

Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes

Donald C Moore et al. J Adv Pract Oncol. 2023 Apr.

Abstract

There has been an increasing number of approvals for targeted therapies and immunotherapies in oncology in the past decade. This has changed the treatment paradigm for many solid tumors and hematologic malignancies, and therefore the outcomes of patients with cancer. Advanced practitioners should be up to date with advances in cancer biomarker testing and its implications for the use of targeted therapy and immunotherapy to integrate this information into clinical decision-making.

PubMed Disclaimer

Conflict of interest statement

Dr. Moore has served on advisory boards for AstraZeneca, Janssen, Pfizer, and Oncopeptides. Mr. Guinigundo has served as a consultant for Amgen, Jazz Pharmaceuticals, and Pharmacosmos, and on speakers bureaus for Amgen, Astellas, GSK, and Pfizer.

References

    1. Armour, A. A., & Watkins, C. L. (2010). The challenge of targeting EGFR: Experience with gefitinib in nonsmall cell lung cancer. European Respiratory Review, 19(117), 186–196. 10.1183/09059180.00005110 - DOI - PMC - PubMed
    1. Bartley, A. N., Mills, A. M., Konnick, E., Overman, M., Ventura, C. B., Souter, L.,…Broaddus, R. R. (2022). Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: Guideline from the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Archives of Pathology & Laboratory Medicine, 146(10), 1194–1210. 10.5858/arpa.2021-0632-CP - DOI - PubMed
    1. Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R., Ozenberger, B. A.,…Stuart, J. M. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 45(10), 1113–1120. 10.1038/ng.2764 - DOI - PMC - PubMed
    1. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L.,…Slamon, D. J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology, 17(9), 2639–2639. 10.1200/jco.1999.17.9.2639 - DOI - PubMed
    1. Cohen, M. H., Williams, G., Johnson, J. R., Duan, J., Gobburu, J., Rahman, A.,…Pazdur, R. (2002). Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical Cancer Research, 8(5), 935–942. https://pubmed.ncbi.nlm.nih.gov/12006504/ - PubMed

LinkOut - more resources